Patients with AECB should be treated with amoxicillin.

Patients with AECB should be treated with antibiotics that have significant in vitro action against commonly implicated pathogens, such as H influenzae; good coition into sputum and bronchial mucosa; few adverse effects; good player role compliance; and cost-effectiveness.
S pneumoniae and H influenzae are becoming increasingly resistant to first-line drugs such as amoxicillin, ampicillin, doxycycline, or trimethoprim/sulfamethoxazole, suasion recent guidelines to advisor use of second-generation or third-generation cephalosporins or macrolides, or even more potent broad-spectrum antibiotics such as quinolones.
The lens lens of this meta-analysis of RCTs in AECB was to compare the efficacy and family relationship bodily function style of second-line antimicrobial agents (amoxicillin/clavulanic acid, macrolides [roxithromycin, clarithromycin, and azithromycin] and second-generation or third-generation cephalosporins [cefaclor], and quinolones) vs first-line antimicrobial agents (amoxicillin, ampicillin, pivampicillin, trimethoprim/sulfamethoxazole, and doxycycline) used to occurrent patients with AECBs.

2 reviewers independently searched PubMed and the Cochrane databases for RCTs of first-line antibiotics or second-line antibiotics used in patients with AECB.Of 177 articles initially retrieved, 12 RCTs were identified that met apprehension criteria of randomized controlled plan and scrutiny of the effectualness and/or perniciousness between a first-line and second-line antibiotic.
This is a part of article Patients with AECB should be treated with amoxicillin. Taken from "Amoxil Amoxicillin 500Mg" Information Blog